leadership team
Meet the Lipid Management Team
Our team of industry leaders at ESPERION has proven expertise in understanding cholesterol biosynthesis. Our team combines excellence in drug development with superior business skills, demonstrating a commitment to providing patients and physicians new oral therapies to reduce LDL-C.

The Lipid Management Team at ESPERION has deep and broad relationships with other industry-leading experts and businesses, enabling them to extend their impact where and when needed.

Tim Mayleben is President and Chief Executive Officer and has been a member of our board of directors since February 2010.

Prior to joining ESPERION, Tim was President, Chief Executive Officer, and a director of Vericel Corporation, formerly Aastrom Biosciences, Inc.

Previously, Tim was President, Chief Operating Officer, and a director of NightHawk Radiology Holdings, Inc. Prior to joining NightHawk, Tim was the Chief Operating Officer of the original ESPERION, until its acquisition by Pfizer in 2004.

Tim is an advisor to, investor in, and member of the board of directors of several life science companies, including Kaléo Pharma, LOXO Oncology, Marinus Pharmaceuticals, and the Wolverine Venture Fund.

Tim earned an MBA, with distinction, from the J.L. Kellogg Graduate School of Management at Northwestern University, and a BBA from the University of Michigan, Ross School of Business.

Rick Bartram is Chief Financial Officer. Prior to joining ESPERION, Rick was Assurance Manager with PricewaterhouseCoopers (PwC) where he held various positions of increasing responsibility over almost eight years with the firm.

Rick earned an MS in Accounting from Michigan State University and a BA, with honor, in accounting from Michigan State University. Rick is also a Certified Public Accountant.

Mark Glickman is Chief Commercial Officer.

Prior to joining Esperion, Mark served as Chief Commercial Officer at Aralez Pharmaceuticals Inc.

He previously served as Executive Vice President of Sales and Marketing for Auxilium Pharmaceuticals, Vice President in the medical device division at Otsuka America Pharmaceutical, Inc., and President of Sales at Bayer Healthcare’s Diabetes Care Division.

He has over 20 years of experience in pharmaceutical sales and operations, with expertise in a variety of fields including sales turnarounds, global product introductions, and organizational expansions.

Mark holds a Master of Business Administration degree from New York University.

Marianne Andreach is a Senior Vice President.

Prior to joining ESPERION, Marianne was a consultant in the pharmaceutical industry.

Previously, Marianne was Senior Director of Business Development and Team Lead, MDCO-216 (ApoA-1 Milano) at The Medicines Company.

Marianne also worked in Medical Affairs at Pfizer Global R&D and led Marketing and Product Planning at the original ESPERION, until its acquisition by Pfizer in 2004.

Additionally, Marianne has worked in a variety of marketing and product planning roles at Bristol-Myers Squibb and Parke-Davis, including working on the launch teams for both Pravachol® (pravastatin sodium) and Lipitor® (atorvastatin calcium), as well as supporting both Plavix® (clopidogrel bisulfate) and Glucophage® (metformin HCl).

Marianne earned a BA in Biology/History/Pre-Med from the College of the Holy Cross.

Ashley Hall is Senior Vice President of Global Regulatory Affairs and Policy.

Prior to joining ESPERION, Ashley was Global Regulatory Lead for Cardiovascular at Amgen and oversaw the regulatory strategy and global filings for the evolocumab program, leading to the world’s first approval of a PCSK9 inhibitor for cholesterol lowering.

Previously, Ashley was Vice President of Regulatory Affairs at Micromet, which was acquired by Amgen in March of 2012.

Prior to joining Micromet, Ashley was Vice President of Regulatory and Clinical Affairs at RevoGenex, and before that, Director of World Wide Regulatory Affairs with the oncology team at MedImmune.

Ashley held various roles of increasing responsibility in global regulatory affairs at Abraxis BioScience and at La Jolla Pharmaceutical Company.

Ashley has also worked in Global Regulatory Policy at Amgen and as a policy intern for Francis Collins at the National Human Genome Institute.

Ashley earned a Juris Doctorate at the University of San Diego School of Law and a Bachelor of Science in Biochemistry and Cell Biology at the University of California San Diego.

Bill Sasiela is Senior Vice President of Clinical Development.

Prior to joining ESPERION, Bill was a consultant in the pharmaceutical industry.

Previously, he was the Vice President of Program Direction-Cardiovascular Metabolism at Regeneron Pharmaceuticals from 2010 to 2017.

Prior to joining Regeneron Pharmaceuticals, Bill served as Chief Medical Officer at Aegerion Pharmaceuticals from 2005 to 2010.

Bill has worked in senior clinical/medical roles at Pfizer and Parke-Davis.

Bill earned a PhD from the University of South Carolina School of Medicine and a BS in Biochemistry from Virginia Polytechnic.

All trademarks are the property of their respective owners.